Hamilton Thorne Ltd. has reported unaudited condensed interim financial results for the quarter and nine months ended September 30, 2024. Revenue was $19.4 million and Adjusted EBITDA was $3.7 million for the quarter.

Hamilton Thorne Ltd., a leading provider of precision instruments, laboratory equipment, consumables, software, and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, is a client of our Bristol Investor Relations firm in Toronto, Canada.

Read the full press release here: Hamilton Thorne Reports Revenue for the Quarter and Nine Months Ended September 30, 2024